Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

dc.creatorMoreira Junior, Edson Duarte
dc.creatorGiuliano, A R
dc.creatorHoon, J de
dc.creatorIversen, O-E
dc.creatorJoura, E A
dc.creatorRestrepo, J
dc.creatorVan Damme, P
dc.creatorVandermeulen, C
dc.creatorEllison, M C
dc.creatorKrick, A
dc.creatorShields, C
dc.creatorHeiles, B
dc.creatorLuxembourg, Alain
dc.date2018-03-16T17:42:41Z
dc.date2018-03-16T17:42:41Z
dc.date2018
dc.date.accessioned2023-09-26T21:10:44Z
dc.date.available2023-09-26T21:10:44Z
dc.identifierMOREIRA JUNIOR, E. D. et al. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Human Vaccines and Immunotherapeutics, v. 14, n. 2, p. 396–403, 2018.
dc.identifier2164-5515
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/25354
dc.identifier10.1080/21645515.2017.1403700
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8870396
dc.descriptionaCentro de Pesquisa Clınica, Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil; bDepartment of Cancer Epidemiology, Center for Infection Research (CIRC), Moffitt Cancer Center, Tampa, Florida, USA; cCenter for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; dDepartment of Clinical Science, University of Bergen/Womens Clinic, Haukeland University Hospital, Bergen, Norway; eDepartment of Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; fFundaci on Centro de Investigaci on Cl ınica CIC, Medell ın, Colombia; gUniversity of Antwerp, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Antwerp, Belgium; hLeuven University Vaccinology Center, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; iMerck & Co. Inc., Kenilworth, New Jersey, USA
dc.descriptionMerck & Co., Inc., Kenilworth, NJ USA
dc.descriptionA 9-valent HPV (9vHPV) vaccine has been developed to protect against HPV type 6/11/16/18/31/33/45/52/58-related infection and disease. Previous safety analyses from 7 clinical trials conducted in 9vHPV vaccine recipients 9-26 years of age, including comparisons of 9vHPV and quadrivalent HPV (qHPV) vaccines in girls and women 16-26 years of age, showed that the 9vHPV vaccine was generally well tolerated. Additional safety analyses were conducted to include the results of new clinical studies. The safety profile of the 9vHPV vaccine in prior qHPV vaccine recipients (n = 3756 from 1 randomized controlled trial and 2 open-label extension studies) and young men (n = 248 9vHPV and n = 248 qHPV vaccine recipients from 1 randomized controlled trial) was evaluated. Vaccine was administered as a 3-dose regimen (at Day 1 and Months 2 and 6), and adverse events (AEs) were monitored. The most common AEs were injection-site events (91.1% and 79.0% in prior qHPV vaccine recipients and young men, respectively), the majority of which were mild. Discontinuations due to an AE were rare (0.2% and 0.0% among prior qHPV vaccine recipients and young men, respectively). In young men, the AE profile of the 9vHPV vaccine was generally similar to that of the qHPV vaccine. Overall, the 9vHPV vaccine was generally well tolerated in prior qHPV vaccine recipients and in young men, with an AE profile generally consistent with that previously reported with the broader clinical program.
dc.formatapplication/pdf
dc.languageeng
dc.publisherTaylor & Francis
dc.rightsopen access
dc.subjectHPV
dc.subjectPapiloma virus humano - HPV
dc.subjectVacinas contra HPV
dc.subject9vHPV
dc.subjectCervical canJEL CODE
dc.subjectVaccines against HPV
dc.titleSafety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
dc.typeArticle


Este ítem pertenece a la siguiente institución